Introduction {#Sec1}
============

The prevalence and disease burden of overweight and obesity is increasing, and data from 1990 to 2015 suggest that obesity is related to nearly four million deaths globally, of which cardiovascular (CV) deaths account for nearly 70% \[[@CR1]\]. Therefore, the various scientific societies recommend to avoid unhealthy fat accumulation for optimal health in most people \[[@CR2]\].

Body mass index (BMI) is the most widely used standardised index to define normal weight, overweight and obesity in clinical practice \[[@CR3]\]. BMI is easy to use, but it does not distinguish between lean body mass and fat mass and its distribution (visceral vs. subcutaneous), and it does not account for biological gender differences in fat function and distribution. Fat mass and its distribution, particularly abdominal fat, is strongly associated with adverse outcomes and data suggest that intra-abdominal (visceral) adipose tissue may be a primary driver of the cardiometabolic complications of obesity \[[@CR4]\].

Most epidemiological studies that include measures of validated indices of body fat or body fat distribution show that these appear to predict CV complications more precisely than BMI \[[@CR5]--[@CR8]\]. Traditional indices of adiposity include waist circumference (WC) and waist-to-hip ratio (WHR), whereas non-traditional, and less studied, indices include WHR (often called index of central obesity, ICO) \[[@CR7], [@CR9]\], a body shape index (ABSI) reflecting abdominal visceral fat \[[@CR10]\] and estimated total body fat (eTBF), which is based on the Young Man's Christian Association's (YMCA) gender-specific formulas \[[@CR11], [@CR12]\].

The aim of this study was to explore the associations of readily available non-traditional (eTBF, ABSI, ICO) and traditional (WC, WHR, BMI) anthropometric indices of fat and fat distribution with long-term CV mortality in the large population-based The Nord-Trøndelag Health Study 2 (HUNT 2) study, and to contrast their ability to predict CV mortality risk in order to identify the best adiposity index for routine clinical use.

Materials and methods {#Sec2}
=====================

Study population {#Sec3}
----------------

HUNT 2 was the second wave of the original HUNT study \[[@CR13]\], a population-based multi-purpose health study in the ethnically homogenous county of Nord-Trøndelag, Norway. This population is considered representative of the total ethnic Norwegian population regarding demography, socio-economic factors, morbidity and mortality, including mortality from CV disease \[[@CR14]\]. For HUNT 2, all residents 20 years or older were invited to a screening visit between August 1995 and July 1997. Subjects responded to a comprehensive health and lifestyle questionnaire and underwent a general health examination. Details of the protocol and study design have been described previously \[[@CR14]\]. For the purpose of this study, we excluded individuals with BMI \<18.5 kg/m^2^ and those with age \<19 or \>79 years.

Anthropometric measures, indices of adiposity and laboratory assessments {#Sec4}
------------------------------------------------------------------------

All exposures were assessed using standardised methodology. Body height and body weight were recorded with the participants wearing light clothes and no shoes. Height was measured to the nearest centimetre and weight to the nearest 0.5 kg. Based on these measures, BMI was calculated as weight (in kg) divided by the squared value of height (in m). WC and hip circumferences were measured with a steel band to the nearest centimetre with the participant standing and with the arms hanging relaxed. The WC was measured horizontally at the height of the umbilicus, and the hip circumference was measured likewise at the thickest part of the hip \[[@CR14]\].

ICO was calculated as WC/height \[[@CR7], [@CR9]\], WHR as WC/hip circumference, eTBF by the sex-specific YMCA formulas (men: 100 × (−98.42 + \[4.15 × WC (in.)\] -- \[0.082 × weight (lbs)\])/weight; females: 100 × (−76.76 + \[4.15 × WC\] -- \[0.082 × weight\])/weight) \[[@CR11], [@CR12]\] and ABSI as WC \[m\]/(BMI^2/3^ × √height \[m\]) \[[@CR10]\].

Systolic and diastolic blood pressure was measured three times and the mean of the two last measurements was used. All blood samples were drawn in the non-fasting state. Participants who either reported to have diabetes mellitus or who had a non-fasting blood glucose above 11.1mL/L at baseline (i.e. at inclusion in HUNT 2) were defined as having diabetes. CV comorbidities at baseline were self-reported by participants (previous myocardial infarction, episode of angina pectoris, or stroke), as were smoking habits ("no smoking", "former smoking" or "current daily smoking of cigarettes, cigars or pipe"). Education was categorised into having completed: primary school, 1--2 years of secondary school, high school, \<4 years of college/university or \>4 years of college/university.

Follow-up and outcome {#Sec5}
---------------------

All participants enrolled in HUNT 2 (1995--1997) included in the present study were followed for CV mortality. Using the participants' unique personal identity number, HUNT 2 data were linked to the Norwegian Cause of Death Registry, to which all deaths in Norway are reported. Death from CV disease was defined according to the International Classification of Disease codes ICD-9: 390--459 for deaths before 2005 and ICD-10: 100--199 for deaths as of 1 January 2005. Subjects were followed until death or until 31 December 2015, whichever occurred first.

Informed consent and ethics {#Sec6}
---------------------------

All participants in HUNT 2 gave written informed consent and the study was approved by the Regional Committee for Medical and Health Research Ethics and by the Norwegian Data Inspectorate. The present study and protocol were approved by the Regional Committee for Medical and Health Research Ethics in 2016.

Statistical analyses {#Sec7}
--------------------

All adiposity indices were categorised into sex-specific quartiles. We used Cox proportional hazard models to explore the associations between the different categories of the indices of adiposity and CV death, with the lowest quartile as the reference category. The proportional hazard assumption was assessed by a test based on Schoenfeld's residuals. We analysed data from men and women separately in crude models as well as in models adjusted for age. To address potential confounding factors, we conducted sensitivity analyses in which we excluded participants with known CV disease, diabetes or current smoking, respectively.

Harrell's *C*-statistics were calculated based on the Cox proportional hazard regression models to assess individual indices' discrimination \[[@CR15]\]. C- index is developed for survival analysis and describes the adiposity index' ability to distinguish between persons with longer event-free survival and those with shorter event-free survival within a given time horizon \[[@CR16]\]. The C-index ranges from a minimum of 0.5 (no discriminatory accuracy) to a theoretical maximum of 1.0 (perfect discrimination). To explore the continuous relationship between the adiposity indices and CV death, we used fractional polynominal plots displaying the HR for CV death for each unit of the adiposity index, for men and women separately. Owing to very low number of participants in the highest ranges of the indices, the graphical displays exclude the 0.5% highest and lowest values for men and women for each adiposity index. We used sex-specific *z*-scores to compare HR for CV death across different adiposity indices.

We analysed relationships between CV mortality and BMI, WC, ICO, WHR, eTBF and ABSI by quartiles of adiposity indices, with the lowest quartile as the reference category. To reduce the influence of competing risk, we excluded those with age ≥80 years and BMI \<18.5 kg/m^2^, and due to gender differences in fat mass distribution/function, we also investigated this relationship for women and men separately. Further, since age and frailty may influence the relationship, we also analysed the associations in two age strata: younger: 19--59 years vs. older: 60--79 years. Absolute risk of CV death was expressed as sex-specific incidence rates per 1000 patient year per quartile of the adiposity indices.

Analyses were performed using SPSS version 24.0 (SPSS Inc., Chicago, IL, USA), STATA version 14 (StataCorp, College Station, TX, USA), and R (R Core Team (2017). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL <https://www.R-project.org/>). In all analyses, *p* \< 0.05 was considered significant.

Results and discussion {#Sec8}
======================

Population characteristics {#Sec9}
--------------------------

Of 92,434 eligible subjects in Nord-Trøndelag County, 66,140 men and women (71.2%) attended the screening. Excluding individuals with BMI \<18.5 kg/m^2^ and not within age-span 19--79 years rendered 61,016 individuals (31,936 women, 29,080 men) to be included in this study, and baseline characteristics are given in Table [1](#Tab1){ref-type="table"}. Male participants, as compared to female participants, had higher weight (83.5 ± 12.2 vs. 70.8 ± 12.5 kg), systolic and diastolic blood pressure (140 ± 19 vs. 135 ± 23 and 82 ± 12 vs. 79 ± 12 mmHg, respectively), *s*-triglycerides (1.9 ± 1.1 vs. 1.5 ± 0.9 mmol/L) and eGFR (96.9 ± 19.8 vs. 92.7 ± 20.9 mL/min/1.73^2^). A larger proportion of men had previous CV disease (8.9 vs. 5.0%). The mean BMI was similar in women and men, whereas the other adiposity indices differed between genders, with the most notable difference observed for the mean WC, which was higher in men (91.9 ± 9.3 vs. 81.5 ± 11.4 cm), and the mean eTBF which was higher in women (19.5 ± 5.5 vs. 27.3 ± 7.4%). In both sexes, there were significant correlations between all adiposity indices (Supplementary Table [1](#MOESM1){ref-type="media"}).Table 1Baseline characteristics of the study population by sexWomen (*n*=31,936)Men (*n*=29,080)*N* with available data*N* with available dataAge (years)48.8 ± 16.131,93648.7 ± 15.829,080DM, *n* (%)898 (2.8%)31,936951 (3.3%)28,975CV disease, *n* (%)^b^1579 (5.0%)31,8492592 (8.9%)29,057Weight (kg)70.8 ± 12.531,93683.5 ± 12.229,080Systolic BP (mmHg)135 ± 2331,861140 ± 1928,963Diastolic BP (mmHg)79 ± 1231,85182 ± 1228,955Cholesterol (mmol/L)^a^5.9 ± 1.331,7135.8 ± 1.128,976Glucose (mmol/L)^a^5.3 ± 0.931,5605.4 ± 1.028,604Triglycerides (mmol/L)^a^1.5 ± 0.931,8381.9 ± 1.128,905eGFR (mL/min/1.73 m^2^) (MDRD)92.7 ± 20.931,84596.9 ± 19.828,998Smoking status31,22528,626 Never smokers14,673(47.0%)10,840 (37.9%) Former smokers7004 (22.4%)9456 (33.0%) Current daily smokers9548(30.6%)8330 (29.1%)   Unknown/missing711 (2.2%)454 (1.6%)Education30,31227,884 Primary school11,857(39.1%)8646 (31.0%)   1--2 years of high school8950 (29.5%)11,307 (40.6%)  Junior college3284 (10.8%)2283 (8.2%)   College/university (\<4 years)4014 (13.2%)3287 (11.8%)   College/university (4 years or more)2207 (7.3%)2361 (8.5)Adiposity indices Waist circumference (cm)81.5 ± 11.431,93691.9 ± 9.329,080 Waist-to-hip ratio0.80 ± 0.0631,9340.90 ± 0.0629,079 BMI (kg/m^2^)26.3 ± 4.531,93626.5 ± 3.529,080 ICO0.50 ± 0.0731,9360.52 ± 0.0529,080 eTBF (%)27.3 ± 7.431,93619.5 ± 5.529,080 ABSI0.72 ± 0.0531,9360.78 ± 0.0429,080*SD* standard deviation, *DM* diabetes mellitus, *eGFR* estimated glomerular filtration rate, *MDRD* modified diet in renal disease, *BMI* body mass index, *ICO* index of central obesity, *eTBF* estimated total body fat, *ABSI* a body shape indexData are given as mean plus/minus SD or proportions^a^Non-fasting^b^Self-reported previous myocardial infarction, episode of angina pectoris or stroke at baseline

Relationships between adiposity indices and CV mortality {#Sec10}
--------------------------------------------------------

The cohort was observed for CV mortality from 1 August 1995 until 31 December 2015, mean observational time 17.7 ± 4.2 (mean ± SD) years, corresponding to 1080, 473.6 person-years. In this period, 13,195 (21.6%) participants died (6136 women, 7059 men), and of these, 4908 (37.2%) died from CV causes (2214 women, 2694 men). Annualised CV mortality rates were 3.9/1000 person-years for women and 5.3/1000 person-years for men, with higher absolute risk of CV death with increasing levels of all adiposity indices (Table [2a](#Tab2){ref-type="table"} and [2b](#Tab3){ref-type="table"}).Table 2aUnadjusted and age-adjusted associations between quartiles of traditional and non-traditional adiposity indices and CV death for womenWomen*N* with available data*N* of CV deathsIncidence rates per 1000 patient yearsUnadjusted HR (95% CI)Age-adjusted HR (95% CI)Waist (cm)31,9362214 ≤73.074641921.3611 73.1--80.080853552.391.77 (1.49--2.11)0.91 (0.76--1.08) 80.1--88.085496814.473.35 (2.85--3.93)0.97 (0.82--1.14) ≥88.178389867.415.64 (4.83--6.59)1.24 (1.06--1.45)Waist-to- hip ratio31,9342214 ≤0.7580222141.4311 0.76--0.7979604102.781.97(1.67--2.32)1.12 (0.95--1.32) 0.80--0.8379485884.122.92 (2.50--3.42)1.11 (0.94--1.30) ≥0.84800410027.465.37 (4.63--6.23)1.49 (1.28--1.73)BMI (m/kg^2^)319362214 ≤23.080783022.0211 23.1--25.579513982.741.36 (1.17--1.58)0.87 (0.75--1.01) 25.6--28.779506144.302.15 (1.87--2.46)0.87 (0.76--1.00) ≥28.879579006.543.30 (2.90--3.76)1.06 (0.93--1.20)ICO31,9362214 ≤0.4479961400.9211 0.45--0.4979623122.112.34 (1.91--2.85)0.97 (0.79--1.19) 0.50--0.5479836304.444.95 (4.12--5.95)1.02 (0.85--1.23) ≥0.55799511328.499.68 (8.12--11.55)1.28 (1.07--1.53)eTBF (%)31,9362214 ≤21.879841160.7611 21.9--27.079953102.092.84 (2.30--3.53)1.15 (0.93--1.43) 27.1--32.279785593.895.31 (4.34--6.49)1.13 (0.93--1.39) ≥32.3797912299.4613.38 (11.05--16.22)1.54 (1.26--1.87)ABSI31,9362214 ≤0.6979842071.3611 0.70--0.7279843242.201.62 (1.36--1.93)0.92 (0.77--1.09) 0.73--0.7579855593.922.95 (2.52--3.46)1.05 (0.89--1.23) ≥0.76798311248.556.60 (5.69--7.66)1.14 (1.14--1.15)*CV* cardiovascular, *HR* hazard ratio, *CI* confidence interval, *WHR* waist-to-hip ratio, *BMI* body mass index, *ICO* index of central obesity, *eTBF* estimated total body fat, *ABSI* a body shape indexTable 2bUnadjusted and age-adjusted associations between quartiles of traditional and non-traditional adiposity indices and CV death for menMen*N* with available*N* of CV deathsIncidence rates per 1000 patient yearsUnadjusted HR (95% CI)Age-adjusted HR (95% CI)Waist (cm)29,0802694 ≤86.072063512.6711 86.1--91.068914974.041.52 (1.32--1.74)1.06 (0.92--1.21) 91.1--97.079077525.492.07 (1.82--2.35)1.09 (0.96--1.24) ≥97.1707610949.583.63 (3.22--4.10)1.40 (1.24--1.58)Waist-to-hip ratio29,0792694 ≤0.8673242862.1411 0.87--0.8972144483.391.67 (1.44---1.94)1.04 (0.89--1.20) 0.90--0.9372377285.812.82 (2.46--3.24)1.20 (1.05--1.38) ≥0.947304123210.855.30 (4.65--6.03)1.47 (1.29--1.68)BMI (m/kg^2^)29,0802694 ≤24.172735224.0911 24.2--26.172986505.071.24 (1.11--1.39)0.99 (0.88--1.11) 26.2--28.472746565.151.26 (1.12--1.41)0.93 (0.83--1.05) ≥28.572358667.071.73 (1.56--1.93)1.20 (1.07--1.33)ICO29,0802694 ≤0.4872912161.6011 0.49--0.5172414663.562.26 (1.92--2.65)1.20 (1.02--1.42) 0.52--0.5572617155.703.62 (3.11--4.22)1.20 (1.03--1.39) ≥0.657287129711.457.31 (6.33--8.45)1.54 (1.33--1.79)eTBF (%)29,0802694 ≤16.072812001.4711 16.1--19.472573922.972.04 (1.72--2.41)1.20 (1.02--1.42) 19.5--23.072726555.173.58 (3.06--4.20)1.20 (1.03--1.39) ≥23.17270144713.269.32 (8.03--10.81)1.54 (1.33--1.79)ABSI29,0802 694 ≤0.7572692351.7111 0.76--0.7872714033.041.77 (1.50--2.08)0.96 (0.82--1.13) 0.79--0.8072706715.333.14 (2.71--3.65)1.10 (0.94--1.28) ≥0.817270138512.717.61 (6.62--8.74)1.38 (1.19--1.59)*CV* cardiovascular, *HR* hazard ratio, *CI* confidence interval, *WHR* waist-to-hip ratio, *BMI* body mass index, *ICO* index of central obesity, *eTBF* estimated total body fat, *ABSI* a body shape index

All indices of adiposity, that is, general fat mass, abdominal fat mass and fat distribution were associated with CV mortality as illustrated in Fig. [1a--f](#Fig1){ref-type="fig"}, displaying HR for CV death by increasing levels of the individual adiposity index. The figures demonstrate a lower risk of CV death in the lowest ranges of the fat indices, and that the apparently most favourable levels of fat mass indices varied across sexes for most of the indices. For some indices, in particular eTBF in women, the risk of CV death seemed to level off at values corresponding to severe obesity. Of note is also the gender effect on CV mortality risk, in particular for eTBF, but also for WC and WHR. The CV mortality risk increases at lower levels of eTBF in men as compared to women, whereas for WC and WHR, the risk increases at slightly lower levels in women as compared to men.Fig. 1**a**--**f** The risk of cardiovascular death (hazard ratio with 95% confidence intervals) according to each unit of the adiposity indices, for men and women separately. **a** Waist circumference, **b** body mass index (BMI), **c** waist-to-hip ratio (WHR), **d** index of central obesity (ICO), **e** estimated total body fat (eTBF), and **f** a body shape index (ABSI) (blue: men; red: women)

The HR for CV death increased by quartiles of adiposity indices (Table [2a](#Tab2){ref-type="table"} and [2b](#Tab3){ref-type="table"}) in men as well as in women. In both genders, the non-traditional index eTBF showed the strongest association (e.g. 4th vs. 1st quartile HR in women 13.38 (95% CI: 11.05--16.22) and in men HR 9.32 (8.03--10.81). Of note is also the weaker association between the HR for CV death and traditional indices, in particular BMI in men. In an age-adjusted model (Table [2a](#Tab2){ref-type="table"} and [2b](#Tab3){ref-type="table"}), the magnitude of association was less for all indices, yet eTBF remained a strong index in men, whereas in women, WHR and eTBF appeared to be of equal strength. Sensitivity analyses excluding participants with high risk for CV death at baseline (known CV disease, diabetes and current smokers) did not alter the associations between the adiposity indices and CV death (data not shown).

Across gender and age strata (Table [3a](#Tab4){ref-type="table"} and [3b](#Tab5){ref-type="table"}), all adiposity indices were related to CV death, but the HRs were somewhat higher in the younger age group, also after age adjustment. Regardless of age stratum, BMI showed the weakest association with CV death, whereas eTBF and ABSI appeared to show the strongest association. After age adjustment however, in the elderly, all indices except BMI seemed to be associated with CV death by similar magnitude.Table 3aUnadjusted and age-adjusted associations between quartiles of the adiposity indices and CV death stratified by age in womenWomen (*n*=31,936)Age19--59 years (*n* = 23,120)19--59 years (*n* = 23,120)60--79 years (*n* = 8816)60--79 years (*n* = 8816)Waist circumference (cm)Unadjusted HR (95% CI)Age-adjusted HR (95% CI)Unadjusted HR (95% CI)Age-adjusted HR (95% CI) 1st quartile1111 2nd quartile1.77 (1.14--2.76)1.24 (0.80--1.94)0.91 (0.76--1.11)0.86 (0.71--1.04) 3rd quartile1.70 (1.07--2.69)0.99 (0.62--1.57)1.13 (0.95--1.35)0.95 (0.80--1.13) 4th quartile3.58 (2.35--5.46)1.75 (1.14--2.69)1.46 (1.24--1.73)1.18 (1.00--1.40)WHR  1st quartile1111  2nd quartile1.62 (1.01--2.60)1.36 (0.85--2.19)1.33 (1.11--1.58)1.07 (0.90--1.28)  3rd quartile2.05 (1.29--3.26)1.42 (0.89--2.25)1.37 (1.16--2.22)1.05 (0.89--1.25)  4th quartile4.05 (2.64--6.22)2.36 (1.53--3.62)1.89 (1.61--2.22)1.40 (1.19--1.64)BMI (kg/m^2^)  1st quartile1111  2nd quartile1.59 (1.04--2.46)1.15 (0.74--1.77)0.82 (0.70--0.96)0.84 (0.71--0.98)  3rd quartile1.66 (1.07--2.58)0.96 (0.62--1.50)0.88 (0.76--1.02)0.86 (0.74--0.99)  4th quartile2.89 (1.92--4.35)1.49 (0.98--2.25)1.07 (0.93--1.22)1.02 (0.89--1.18)ICO  1st quartile1111  2nd quartile1.94 (1.23--3.08)1.28 (0.80--2.02)1.00 (0.80--1.25)0.91 (0.73--1.13)  3rd quartile2.57 (1.63--4.05)1.38 (0.87--2.19)1.23 (1.01--1.51)0.95 (0.78--1.13)  4th quartile4.46 (2.88--6.89)1.99 (1.28--3.10)1.67 (1.37--2.03)1.18 (0.97--1.43)eTBF (%)  1st quartile1111  2nd quartile2.00 (1.23--3.23)1.38 (0.85--2.24)1.27 (1.00--1.61)1.07 (0.84--1.36)  3rd quartile2.90 (1.82--4.63)1.63 (1.02--2.62)1.41 (1.13--1.77)1.02 (0.81--1.28)  4th quartile5.88 (3.75--9.21)2.67 (1.69--4.20)2.21 (1.78--2.75)1.37 (1.10--1.70)ABSI  1st quartile1111  2nd quartile1.31 (0.82--2.11)1.06 (0.66--1.70)1.01 (0.84--1.22)0.88 (0.73--1.06)  3rd quartile2.39 (1.55--3.69)1.62 (1.05--2.50)1.27 (1.07--1.51)0.97 (0.82--1.15)  4th quartile3.72 (2.44--5.66)2.16 (1.41--3.30)2.00 (1.71--2.35)1.33 (1.13--1.57)*CV* cardiovascular, *HR* hazard ratio, *CI* confidence interval, *WHR* waist-to-hip ratio, *BMI* body mass index, *ICO* index of central obesity, *eTBF* estimated total body fat, *ABSI* a body shape indexTable 3bUnadjusted and age-adjusted associations between quartiles of the adiposity indices and CV death stratified by age in menMen (*n*=29,080)Age19--59 years (*n* = 21,237)19--59 years (*n* = 21,237)60--79 years (*n* = 7843)60--79 years (*n* = 7843)Waist circumference (cm)Unadjusted HR (95% CI)Age-adjusted HR (95% CI)Unadjusted HR (95% CI)Age-adjusted HR (95% CI) 1st quartile1111 2nd quartile1.72 (1.25--2.37)1.20 (0.87--1.64)1.02 (0.88--1.19)1.03 (0.88--1.20) 3rd quartile2.01 (1.48--2.74)1.20 (0.88--1.63)1.15 (1.00--1.32)1.06 (0.92--1.22) 4th quartile4.12 (3.09--5.50)2.10 (1.57--2.81)1.41 (1.23--1.61)1.29 (1.13--1.48)WHR  1st quartile1111  2nd quartile1.62 (1.17--2.25)1.10 (0.79--1.53)1.06 (0.90--1.25)1.01 (0.86--1.20)  3rd quartile2.76 (2.04--3.75)1.54 (1.13--2.09)1.22 (1.04--1.42)1.13 (0.96--1.32)  4th quartile4.58 (3.40--6.15)1.97 (1.46--2.67)1.59 (1.38--1.84)1.37 (1.18--1.59)BMI (kg/m^2^)  1st quartile1111  2nd quartile1.42 (1.04--1.92)1.09 (0.80--1.47)0.97 (0.86--1.10)0.97 (0.86--1.10)  3rd quartile1.59 (1.18--2.13)1.07 (0.80--1.44)0.87 (0.77--0.98)0.91 (0.80--1.03)  4th quartile2.65 (2.02--3.49)1.67 (1.27--2.20)1.06 (0.94--1.19)1.12 (0.99--1.26)ICO  1st quartile1111  2nd quartile2.58 (1.85--3.62)1.64 (1.17--2.30)1.04 (0.86--1.25)1.08 (0.89--1.29)  3rd quartile2.83 (2.01--3.97)1.44 (1.02--2.03)1.20 (1.01--1.42)1.09 (0.92--1.29)  4th quartile6.65 (4.84--9.12)2.86 (2.08--3.95)1.57 (1.34--1.85)1.31 (1.11--1.54)eTBF (%)  1st quartile1111  2nd quartile2.34 (1.67--3.26)1.53 (1.09--2.14)1.04 (0.85--1.27)1.08 (0.89--1.32)  3rd quartile3.32 (2.40--4.58)1.71 (1.23--2.37)1.20 (1.00--1.44)1.10 (0.92--1.32)  4th quartile6.45 (4.70--8.86)2.58 (1.87--3.56)1.83 (1.54--2.17)1.42 (1.20--1.68)ABSI  1st quartile1111  2nd quartile1.25 (0.94--1.66)0.94 (0.71--1.26)1.07 (0.88--1.31)0.95 (0.78--1.16)  3rd quartile1.78 (1.35--2.34)1.10 (0.83--1.45)1.34 (1.12--1.61)1.08 (0.90--1.30)  4th quartile3.15 (2.41--4.12)1.62 (1.23--2.12)2.00 (1.68--2.37)1.32 (1.11--1.58)*CV* cardiovascular, *HR* hazard ratio, *CI* confidence interval, *WHR* waist-to-hip ratio, *BMI* body mass index, *ICO* gindex of central obesity, *eTBF* estimated total body fat, *ABSI* a body shape index

The discriminative ability of the different indices as expressed by *C*-statistics is shown in Table [4](#Tab6){ref-type="table"}. In both women and men, the discriminative ability of eTBF was robust (\>0.7) and appeared to best capture the risk for CV death together with ICO in women and ABSI in men. When analysing sex-specific *z*-scores by individual adiposity indices, both eTBF and ABSI were strongly associated with CV death (Fig. [2](#Fig2){ref-type="fig"}).Table 4*C*-statistics for unadjusted models of the traditional and non-traditional adiposity indices in prediction of CV death*C*-statistics (95% confidence interval)WomenMeneTBF0.725 (0.713--0.737)0.711 (0.701--0.721)ICO0.704 (0.692--0.716)0.682 (0.672--0.692)ABSI0.690 (0.678--0.702)0.700 (0.690--0.710)Waist circumference0.663 (0.651--0.675)0.626 (0.616--0.636)WHR0.659 (0.647--0.671)0.664 (0.654--0.674)BMI0.622 (0.610--0.634)0.551 (0.541--0.562)*WHR* waist-to-hip ratio, *BMI* body mass index, *ICO* index of central obesity, *eTBF* estimated total body fat, *ABSI* a body shape indexFig. 2The risk of cardiovascular death (hazard ratio) according to standardised adiposity indices (standardised by sex-specific *z*-scores of each adiposity index). WHR: waist-to-hip ratio, BMI: body mass index, ICO: index of central obesity, eTBF: estimated total body fat, ABSI: a body shape index

In this large, population-based study with observation of individuals for more 17 years comprising more than one million person-years, we found that the non-traditional adiposity index eTBF was the strongest discriminator of CV death in both men and women. This index discriminated better than the traditional indices (BMI, WC and WHR), and on par with ICO in women and ABSI in men. To our knowledge, this is the first study to assess the discriminative property of the sex-specific adiposity index eTBF, a new and easy-to-calculate index that may be useful for clinicians for CV risk estimation.

The relationship between risk for CV mortality and overweight is complex. However, studies that have evaluated the association between obesity and life expectancy have shown that extreme obesity may shorten life expectancy up to 14 years \[[@CR17]\] and that the obesity-associated mortality has increased over the past decades \[[@CR18]--[@CR20]\]. BMI is the most commonly used tool for clinicians to classify obesity. However, acknowledging the already mentioned limitations of BMI, it is debated whether BMI is an appropriate measure to identify obesity related CV risk \[[@CR21], [@CR22]\]. A more accurately defined risk score may help the health care provider to emphasise the importance of reduction of weight and body fat \[[@CR23]\], and better indices of adiposity than BMI are thus needed. Assessment of fat mass by the gold-standard approach requires imaging techniques, which are impossible to implement in clinical practice due to high cost, radiation exposure, and long scan time. Surrogate indices of total adiposity like eTBF, which is highly correlated with total body fat content as measured by dual x-ray absorptiometry (DXA) \[[@CR23], [@CR24]\], is therefore an applicable tool for estimation of CV mortality risk associated with adiposity.

Previous analyses of non-traditional adiposity indices, including a former analysis of the present cohort with fewer years of follow-up \[[@CR5]\], did not evaluate ABSI or eTBF, but in general, these studies support the notion that non-traditional indices of obesity are more strongly associated with CV mortality than BMI \[[@CR8], [@CR25], [@CR26]\].

We found that measures of visceral fat such as WC and WHR, traditionally regarded to be better predictors of mortality than BMI, were weaker discriminators for CV mortality risk than eTBF. One reason could be that eTBF, unlike the others, is gender specific, and thus incorporates the gender disparity in adipose function \[[@CR27]--[@CR30]\] and distribution \[[@CR31]\], that is, women tend to have higher levels of subcutaneous fat for a given BMI or WC \[[@CR32]\]. This could also explain the higher mortality risk at lower eTBF levels in men seen in Fig. [1](#Fig1){ref-type="fig"}. Further, as the eTBF formula encompasses both WC and weight, it may reflect other important fat depots, for example, epicardial or intramuscular, which are missed when WC, the hip circumference or height alone or in combination are assessed. In accordance with this, a previous study from Iceland demonstrated that the amount of intermuscular fat in the thigh was associated with increased mortality in subjects aged 66--96 years \[[@CR33]\]. The finding is in accordance with the present report showing that eTBF was a better discriminator for CV death than ICO in men and likely women (Table [4](#Tab6){ref-type="table"}). However, ICO is a better predictor than BMI \[[@CR5], [@CR7], [@CR8], [@CR25], [@CR26], [@CR34]\] and ICO correlates well with the amount of visceral fat tissue by MRI \[[@CR24]\]. Another potential explanation for our finding is the possibility that eTBF reflects different cardiometabolic risk than that expressed by the amount of visceral or total body fat, for example, risk related to the relative amount of the two fat compartments or gender. More extensive validation of eTBF in another population is necessary to verify our findings, and to investigate whether reduction of eTBF would translate into a lower CV risk.

The other two non-traditional adiposity indices, ABSI and ICO, were both more strongly associated with CV death than the established measures (BMI, WC and WHR). ABSI was derived from a US general population sample and incorporates WC and BMI, and thus requires the measurement of height, unlike eTBF \[[@CR10]\]. High ABSI indicates that WC is higher than expected for a given height and weight and suggests abdominal obesity. We found that ABSI seemed to discriminate better than ICO in men, whereas in women, ICO was better than ABSI, although the confidence intervals were overlapping for both sexes (Table [4](#Tab6){ref-type="table"}). These findings are in line with other studies of ABSI in both elderly \[[@CR6]\] and middle-aged populations \[[@CR35]\]. A gender disparity of ABSI is also in accordance with previous findings \[[@CR36]\]. In men, ABSI was positively correlated to the fat mass index, and negatively correlated to DXA-measured fat-free mass index, whereas in women, ABSI was positively correlated to both fat mass index and fat-free mass index \[[@CR36]\]. This discrepancy may reflect the difference in body composition between genders, with a tendency of accumulation of fat centrally in men, and in the gluteal--femoral region in women \[[@CR37]\], and may explain why ABSI may not be able to identify or discriminate the hazardous abdominal visceral fat from other tissue as well in women as in men.

Age modified the association of all adiposity indices' to CV mortality risk as indicated in Table [2a](#Tab2){ref-type="table"} and [2b](#Tab3){ref-type="table"} and in the age-strata analysis (Table [3a](#Tab4){ref-type="table"} and [3b](#Tab5){ref-type="table"}), underscoring that age is a risk modifier, in line with other studies \[[@CR6], [@CR35], [@CR38]\]. Nevertheless, also in the elderly, we find a "dose response" between increasing quartiles of all adiposity indices and risk of CV death, except for BMI. This may be explained by BMI's lacking ability to capture body composition and body fat distribution: as age advances, lean body mass decreases and fat mass increases with a preferential distribution in the abdominal region \[[@CR39]\].

As shown in Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}, the relationship between all the adiposity indices and risk of CV death were close to linear up to higher levels of adiposity, in women as well as in men. Interestingly, at higher levels of all adiposity indices, except for BMI in men, the associated risk of CV death seemed to level off. This may potentially be explained by competing risks, "the obesity paradox" \[[@CR40]\], or be an artefact due to lower sample size in the higher ranges of adiposity.

The strengths of this study are the large number of participants, the population-based prospective design, the objectively measured body height, weight, and waist and hip circumference and the completeness of the data set, enhancing the generalisability of our results. Furthermore, the homogeneity of the population is of importance, since ethnicity and racial differences in body composition influence the associations of anthropometric measures with CV outcomes. However, our findings may not be generalised beyond Caucasians, since our dataset does not include African Americans or Asians. The principal limitation of our study, as of other registry-based studies, is the restricted possibility to address all potential confounding factors.

In this population-based study with more than one million person-years of observation, the gender-specific adiposity index eTBF was associated with CV death in men as well as in women, and more so than other non-traditional and traditional adiposity indices. eTBF reflects the amount of total body fat, is easily calculated and may thus be a suitable clinical tool for assessment of obesity-associated CV risk.
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